Cargando…
Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
Standard of care therapies for autosomal dominant polycystic kidney disease (ADPKD) may limit morbidity and mortality due to disease-related complications, but they do not delay disease progression. Tolvaptan, a selective vasopressin V2 receptor antagonist, delays the increase in kidney volume (a su...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797468/ https://www.ncbi.nlm.nih.gov/pubmed/29430193 http://dx.doi.org/10.2147/IJNRD.S125942 |